Ubrelvy (generic name: ubrogepant) is an FDA-approved oral medication for the acute treatment of migraine attacks in adults, whether or not accompanied by aura. Unlike traditional migraine treatments such as triptans, Ubrelvy belongs to a newer class of medicines known as calcitonin gene-related peptide (CGRP) receptor antagonists. CGRP is a protein that increases during migraine attacks and contributes to pain transmission and inflammation.

By selectively blocking CGRP receptors, Ubrelvy helps relieve headache pain, nausea, and sensitivity to light and sound associated with migraine. It is not intended for the prevention of migraines but is taken at the onset of symptoms.

Ubrelvy is available in 50 mg and 100 mg tablets, taken orally. A second dose may be taken at least 2 hours after the first if symptoms persist, with a maximum of 200 mg in 24 hours.

Key points about Ubrelvy:

• Approved for adults only.

• Works without causing blood vessel constriction (unlike triptans).

• May be suitable for people who cannot tolerate or do not respond well to triptans.

• Common side effects include nausea, drowsiness, and dry mouth.

• Not habit-forming and has a low risk of medication overuse headache.